Candida albicans-Staphylococcus aureus polymicrobial peritonitis modulates host innate immunity.

Area of Science:

• Infectious Diseases
• Immunology
• Microbiology

Background:

• Polymicrobial peritonitis (fungal-bacterial) poses a significant threat to surgical patients, dialysis patients, and the critically ill.
• While single infections with Candida albicans or Staphylococcus aureus are survivable, their coinfection leads to high mortality and organ burden.

Purpose of the Study:

• To investigate the mechanisms underlying the increased mortality in fungal-bacterial peritonitis.
• To identify key inflammatory mediators involved in polymicrobial peritonitis.
• To evaluate the therapeutic potential of targeting inflammatory pathways.

Main Methods:

• Murine model of fungal-bacterial peritonitis.
• Multiplex enzyme-linked immunosorbent assay (ELISA) for cytokine analysis.
• Administration of cyclooxygenase (COX) inhibitor indomethacin and prostaglandin E2 (PGE2).

Main Results:

• Coinfection significantly increased mortality (40%) and microbial burden compared to monomicrobial infections.
• Elevated levels of specific proinflammatory cytokines (IL-6, G-CSF, KC, MCP-1, MIP-1α) were observed during coinfection.
• Indomethacin treatment reduced infectious burden, cytokine production, inflammatory infiltrate, and prevented mortality.
• Exogenous PGE2 administration reversed the protective effects of indomethacin, increasing mortality and microbial burden.

Conclusions:

• Fungal-bacterial coinfection synergistically enhances innate inflammatory responses, leading to severe outcomes.
• Prostaglandin E2 (PGE2) plays a critical role in mediating the increased inflammation and mortality.
• Targeting cyclooxygenase (COX) pathways with indomethacin offers a promising therapeutic strategy for polymicrobial peritonitis.